TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various
Acrylamides
/ pharmacology
Aniline Compounds
/ pharmacology
Animals
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Cell Proliferation
/ drug effects
Drug Resistance, Neoplasm
/ drug effects
ErbB Receptors
/ antagonists & inhibitors
Gene Expression Regulation, Neoplastic
/ drug effects
HEK293 Cells
Heterografts
Humans
Mice
Mutation
/ genetics
Protein Kinase Inhibitors
/ pharmacology
Pyrimidines
/ pharmacology
Quinolines
/ pharmacology
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
13
06
2018
revised:
10
10
2018
accepted:
07
03
2019
pubmed:
16
3
2019
medline:
24
3
2020
entrez:
16
3
2019
Statut:
ppublish
Résumé
TAS-121 is a novel orally active selective covalent inhibitor of the mutant EGFR. We performed preclinical characterization of TAS-121 and compared its efficacy and selectivity for common
Identifiants
pubmed: 30872380
pii: 1535-7163.MCT-18-0645
doi: 10.1158/1535-7163.MCT-18-0645
doi:
Substances chimiques
Acrylamides
0
Aniline Compounds
0
Protein Kinase Inhibitors
0
Pyrimidines
0
Quinolines
0
TAS-121
0
osimertinib
3C06JJ0Z2O
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
920-928Informations de copyright
©2019 American Association for Cancer Research.